Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06639711

Taurine Eye Drops May Prevent the Progression of Cataract

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract? * The acceptance/ compliance of participants to taurine-containing eye drops. * Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year. * Visit eye clinic every 3 months for assessment and visual examination. * Keep notes for their symptoms and their adherence to treatment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Al-Nahrain Eye Clinics

Ramadi, Al-Anbar Governorate, 31001, Iraq

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The presence of grade I or II senile cataract on one or two eyes.

Exclusion criteria

  • clinical signs of glaucoma
  • history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
  • history of iritis, retinal crystalline deposits, or optic nerve disease
  • visually significant fundus pathology

Treatment and study plan

Taurine

Drug

Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year

Other names: VIZILOTIN Eye Drops

Primary outcomes

  1. Visual Acuity

    Time frame: 1 Year

Sponsors and collaborators

Lead sponsor

University Of Anbar

Other

Registry information

Official study title

Taurine Affects the Progression of Senile Cataract: a Single-arm Pre-post Intervention Study

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 15, 2024
Registry last updated
Dec 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.